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Abstract
Primary intestinal lymphangiectasia (PIL) is a rare disorder characterized by dilated intestinal
lacteals resulting in lymph leakage into the small bowel lumen and responsible for protein-losing
enteropathy leading to lymphopenia, hypoalbuminemia and hypogammaglobulinemia. PIL is
generally diagnosed before 3 years of age but may be diagnosed in older patients. Prevalence is
unknown. The main symptom is predominantly bilateral lower limb edema. Edema may be
moderate to severe with anasarca and includes pleural effusion, pericarditis or chylous ascites.
Fatigue, abdominal pain, weight loss, inability to gain weight, moderate diarrhea or fat-soluble
vitamin deficiencies due to malabsorption may also be present. In some patients, limb lymphedema
is associated with PIL and is difficult to distinguish lymphedema from edema. Exsudative
enteropathy is confirmed by the elevated 24-h stool α1-antitrypsin clearance. Etiology remains
unknown. Very rare familial cases of PIL have been reported. Diagnosis is confirmed by endoscopic
observation of intestinal lymphangiectasia with the corresponding histology of intestinal biopsy
specimens. Videocapsule endoscopy may be useful when endoscopic findings are not contributive.
Differential diagnosis includes constrictive pericarditis, intestinal lymphoma, Whipple's disease,
Crohn's disease, intestinal tuberculosis, sarcoidosis or systemic sclerosis. Several B-cell lymphomas
confined to the gastrointestinal tract (stomach, jejunum, midgut, ileum) or with extra-intestinal
localizations were reported in PIL patients. A low-fat diet associated with medium-chain
triglyceride supplementation is the cornerstone of PIL medical management. The absence of fat in
the diet prevents chyle engorgement of the intestinal lymphatic vessels thereby preventing their
rupture with its ensuing lymph loss. Medium-chain triglycerides are absorbed directly into the
portal venous circulation and avoid lacteal overloading. Other inconsistently effective treatments
have been proposed for PIL patients, such as antiplasmin, octreotide or corticosteroids. Surgical
small-bowel resection is useful in the rare cases with segmental and localized intestinal
lymphangiectasia. The need for dietary control appears to be permanent, because clinical and
biochemical findings reappear after low-fat diet withdrawal. PIL outcome may be severe even life-
threatening when malignant complications or serous effusion(s) occur.
Disease name and synonyms
Primary intestinal lymphangiectasia (PIL).
Waldmann's disease.
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History and definition
In 1961, Waldmann et al. described the first 18 cases of
"idiopathic hypercatabolic hypoproteinemia" [1]. These
patients had edema associated with hypoproteinemia,
low serum albumin and gammaglobulin levels. The total
exchangeable albumin pool, assessed with radio-labeled
131I-albumin, was low in all patients. Daily fecal excretion
of 131I was twice the highest value obtained in controls.
Microscope examination of the small intestine biopsies
showed variable degrees of dilation of the lymph vessels
in the mucosa and submucosa. The authors also proposed
the term "intestinal lymphangiectasia".
Epidemiology
The prevalence of clinically overt PIL is unknown. How-
ever, PIL can be asymptomatic; it primarily affects chil-
dren (generally diagnosed before 3 years of age) and
young adults but may be diagnosed later in adults [2,3].
Very rare familial forms of Waldmann's disease have been
reported [1,4].
Clinical description
A. Edema
Peripheral edema of variable degree, usually symmetrical,
from moderate (lower limb edema) to severe, including
the face and external genitalia, is the main clinical feature,
which accounts for 95% of PIL clinical manifestations [4].
Moderate serous effusions (pleural effusion, pericarditis,
chylous ascites) are common, and life-threatening ana-
sarca may occur rarely throughout the course of the dis-
ease [1,5]. The edema is pitting because the oncotic
pressure is low due to hypoalbuminemia resulting from
exsudative enteropathy. PIL may be suspected at birth or
during pregnancy based on ultrasonography images,
which can detect fetal ascites or lower limb lymphedema
[6].
B. Childhood particularities
In children, PIL is generally diagnosed before 3 years of
age [5,7,8] and may be complicated by fatigue, abdominal
pain, nausea, vomiting and weight loss, inability to gain
weight and growth retardation [5]. Malabsorption may
cause fat-soluble vitamin deficiencies and hypocalcemia
leading to convulsions [5].
C. Other clinical findings
- Lymphedema  is a rare disorder which is usually not
associated with another disease, but it may be associated
with intestinal lymphangiectasia. Clinical features of
lymphedema are specific (Figure 1). Lymphedema is less
pitting than edema due to hypoproteinemia, and is local-
ized to the lower limbs (foot, ankle, calf, rarely thigh) and
predominantly bilateral. Upper limb with hand and fore-
arm involvement, lymphedema of breast and external
genitalia (with skin thickening) may also be present [9].
In most patients with lymphedema, edema as a conse-
quence of hypoproprotidemia has also been observed.
The two types of edema are not always easily distin-
guished. Stemmer's sign is an important element to con-
firm the diagnosis and differentiate lymphedema from
edema: i.e., it is impossible to lift and wrinkle the dorsal
skin on the second toe because of skin-thickening as the
result of fibrosis.
- Moderate or discontinuous diarrhea is the main diges-
tive symptom [10].
- An abdominal mass was found in the epigastrium and
right upper quadrant of a 12-year-old girl. Ultrasonogra-
phy failed to confirm an abdominal mass but the mass
was attributed to small bowel edema [11].
- A malabsorption syndrome may be encountered in the
elderly [12].
- Mechanical ileus of the small intestine caused by local-
ized edema leading to intestinal wall-thickening and
lumen diminution. It may be visualized as a segmental
mass requiring resection (histological findings: dilation of
submucosal lymphatics, extensive pseudocysts in the jeju-
nal wall, intramural lymph edema, secondary bleeding,
tight stenosis of the jejunal lumen) [13].
- Chylous reflux into the skin of the right flank resembles
lymphangioma circumscriptum with multiple dome-
shaped vesicles filled with milky-white fluid, which is dis-
charged into the surrounding skin [14].
- Chyle can also backflow into the skin of the lower limb,
perineum or external genitalia [15].
- An association with celiac disease has been reported in
children [16].
-  Iron deficiency with anemia occurs secondary to
chronic blood loss resulting from non-specific multiple
ulcers in the small intestine [17].
- Necrolytic migratory erythema can be seen [18].
-  Recurrent hemolytic uremic syndrome has been
described [19].
- Osteomalacia resulting from vitamin D deficiency was
reported in a 63-year-old woman [20].
- It remains open to debate whether recurrent gastroin-
testinal bleeding is indeed a manifestation of PIL [21].Orphanet Journal of Rare Diseases 2008, 3:5 http://www.ojrd.com/content/3/1/5
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D. Syndromes associated with intestinal lymphangiectasia
First described in 1964 by Samman and White, the yellow
nail syndrome is a very rare condition which may be asso-
ciated with PIL. Dystrophic yellow nails with ridging and
loss of lunula on the hands are associated with lymphe-
dema and pleural effusions [22].
Five syndromes are associated with intestinal lym-
phangiectasia: von Recklinghausen, Turner (X0) or Noo-
nan, Klippel-Trenaunay and Hennekam [23]. In general,
these syndromes are easily distinguishable by the presence
of facial abnormalities (Turner, Noonan, Hennekam),
mental retardation (Hennekam, Noonan), seizures (Hen-
nekam), severe limb and/or face lymphedema (Hen-
nekam), neurofibromas and other tumors (von
Recklinghausen), and hemihypertophy of the limbs asso-
ciated with vascular malformations (Klippel-Trenaunay).
Etiology and pathogenesis
To date, PIL etiology is unknown. Intestinal lym-
phangiectasia is responsible for lymph leakage into the
bowel lumen, which leads to hypoalbuminemia and lym-
phopenia. Edema is the consequence of hypoprotidemia
with decreased oncotic pressure. Several genes, such as
VEGFR3 (vascular endothelial growth factor receptor 3),
prospero-related homeobox-transcriptional factor
PROX1, forkhead transcriptional factor FOXC2  and
SOX18  are implicated in the development of the lym-
phatic system. In a recent paper, Hokari et al. reported
inconsistently changed expressions of regulatory mole-
cules for lymphangiogenesis in the duodenal mucosa of
PIL patients [24].
Diagnosis and diagnostic methods
PIL diagnosis is confirmed by the presence of intestinal
lymphangiectasia based on endoscopic findings with the
corresponding histology of intestinal biopsy specimens
(Figure 2). Macroscopic abnormalities are usually obvious
with creamy yellow of jejunal villi corresponding to
marked dilation of the lymphatics within the intestinal
mucosa. The density of lymphangiectasia varies and their
size ranges from mm to cm. Histological examination of
duodenum-jejunum and ileum biopsies confirms the
presence of lacteal juice, dilated mucosal (from moderate
to severe) and submucosal lymphatic vessels (and also in
the serosa) with polyclonal normal plasma cells. Intesti-
nal lymphatics may be dilated in many villi or only a few.
Intestinal abnormalities may be slight; small bowel
mucosa also appears edematous but not creamy. That nei-
ther villous atrophy nor microorganisms are found in
biopsies is underlined in pathology reports. Endoscopy
may be negative when intestinal lesions are segmental or
localized. In such cases, videocapsule endoscopy, easier to
use than enteroscopy, is a useful tool to detect the pres-
ence of intestinal lymphangiectasia and to specify its
localization (Figure 3) [25-27]. Videocapsule endoscopy
A 23-year-old woman with PIL since infancy Figure 1
A 23-year-old woman with PIL since infancy. Note the 
bilateral lower limb lymphedema, with accentuation of the 
dorsal flexion folds of the toes.
Duodenal biopsy: note the markedly dilated lymphatic ducts  (periodic acid Schiff staining) Figure 2
Duodenal biopsy: note the markedly dilated lym-
phatic ducts (periodic acid Schiff staining).Orphanet Journal of Rare Diseases 2008, 3:5 http://www.ojrd.com/content/3/1/5
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is also feasible to appreciate the extent of lymphangiecta-
sia in children [28].
Indirect biological abnormalities are suggesting of PIL,
such as hypoproteinemia, hypoalbuminemia, hypogam-
maglobulinemia with low IgG, IgA and IgM levels or lym-
phocytopenia. Exsudative enteropathy is confirmed by
the high 24-h stool α1-antitrypsin clearance due to enteric
protein loss. Functional absorption tests, e.g., such as D-
xylose test results are normal in PIL.
Complementary examinations
Although various methods have been proposed to investi-
gate PIL, none of them can replace histological examina-
tion of biopsies to confirm the diagnosis.
A. Albumin scintigraphy
99mTechnetium-labeled human serum albumin (99mTc-
HSA) scintigraphy may show marked enhancement in the
bowel, which indicates protein leakage into this region
[23]. Serial scanning for up to 24 h is required to detect
protein loss from the gut, perhaps because of the intermit-
tent nature of protein loss. 99mTc-HSA scintigraphy has
high sensitivity and is able to identify the site of protein
loss (large and/or small bowel localization, stomach)
[29]. The α1-antitrypsin method has replaced 99mTc-HSA
scintigraphy, which is more costly, less readily available
and also uses a human product potentially carrying an
infectious risk.
B. Ultrasound
Indirect features may suggest PIL in children and adults.
Ultrasonographic findings may show dilation of the intes-
tinal loops, regular and diffuse thickening of the walls, pli-
cal hypertrophy and severe mesenteric edema and, in
some cases, ascites [30,31].
C. Computed tomography (CT) scans
Axial abdominal CT images are obtained with oral and
intravenous contrast medium enhancement. CT appear-
ance of PIL is similar in adults and children. Typically,
there is diffuse, nodular, small bowel wall-thickening and
edema, which are a consequence of the dilated lymphatics
within the villi, along with some degree of small bowel
dilation, with, in few cases, a "halo sign" due to swelling
and edema [32-34]. CT may be useful to identify localized
intestinal lymphangiectasia [35].
D. Lymphoscintigraphy
Lymphoscintigraphy is an effective tool for identifying
abnormal lymphatic tree in the upper or lower limb and
also to confirm limb lymphedema, when the limb images
are abnormal. In limb lymphedema, isotope-uptake seen
on the lymphogram shows an absence of visible lymph
nodes which indicates either peripheral lymphatic obliter-
ation or inability of the vessels to transport lymph up the
limb through incompetent lymphatic vessels [36]. 99mTc-
radio-labeled rhenium sulfur colloid and albumin colloid
are the two isotopes currently used in limb lymphoscintig-
raphy. At present, lymphoscintigraphy is not a routine
and useful methodology for PIL diagnosis. Indeed, in one
study, So et al. reported that intestinal lymphoscintigra-
phy (after subcutaneous injection of 99mTc-antimony
sulfide colloid into the two first toe spaces) only detected
the presence of radioactivity in less than half of patients
with histologically proven PIL [37].
Immunological abnormalities
PIL patients have immunological abnormalities involving
both the B-cell and T-cell lineages of the immune system.
The B-cell defect is characterized by low immunoglobulin
levels (IgG, IgA and IgM) and poor antibody responses
[38-40]. The T-cell defect is characterized by lymphocyto-
penia, prolonged skin-allograft rejection and impaired in
vitro proliferative responses to various stimulants (anti-
CD3, anti-CD28) [41]. Furthermore, PIL patient's periph-
eral blood samples contain extremely low counts of CD4+
T cells, especially naïve, CD45RA+  CD62L+, while
CD45RO+ memory cells, are only moderately below nor-
mal. CD45RA+ and CD45RO+ CD8+ T cells are moderately
below normal [41].
Capsule endoscopy (M2A, Given Imaging, Yoqneam, Israel):  note the edematous aspect of the jejunum mucosa with whit- ish, swollen villi Figure 3
Capsule endoscopy (M2A, Given Imaging, Yoqneam, 
Israel): note the edematous aspect of the jejunum 
mucosa with whitish, swollen villi.Orphanet Journal of Rare Diseases 2008, 3:5 http://www.ojrd.com/content/3/1/5
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Differential diagnosis
The differential diagnosis is of special importance for sub-
jects suspected of having PIL. Some secondary causes of
intestinal lymphangiectasia have been identified as dis-
eases responsible for anatomical or dynamic alterations of
the lymphatic flow. Protein-losing enteropathies associ-
ated with intestinal lymphangiectasia may arise secondary
to constrictive pericarditis [42-44], intestinal lymphoma
[45,46], lymphenteric fistula [47], Whipple's disease [48],
Crohn's disease [49], sarcoidosis [50], intestinal tubercu-
losis [51], systemic sclerosis [52], radiation and/or chem-
otherapy with retroperitoneal fibrosis [53], human
immunodeficiency virus-related enteropathy [54] or the
Fontan operation to treat cardiac malformations [55].
Many diseases are associated with excessive enteric loss of
plasma proteins but do not include lymphatic lym-
phangiectasia, such as Menetrier's disease or inflamma-
tory states of systemic lupus erythematosus in adults and
children [56-59].
Complications
A. Malignant transformation
It is not clear whether the occurrence of malignancy, espe-
cially lymphomas, is fortuitous or related to PIL. Indeed,
only a few lymphomas associated with PIL have been
reported. Among 50 PIL patients reviewed, 3 had malig-
nant lymphomas, that arose 3 to 25 years after the initial
diagnosis [60]. The interval from PIL diagnosis to lym-
phoma diagnosis was even 39 and 40 years in a study [61].
Some lymphomas were confined to the gastrointestinal
tract (stomach, jejunum, midgut, ileum), i.e. in PIL
involved sites, while in other patients they were extra-
intestinal (retroperitoneum, mediastinum, bone) [60-
63]. In the well-described histological and immunological
studies, only B-cell lymphomas (large cells, small cells,
centroblastic, immunoblasts) were encountered [61].
Chemotherapy achieved regression of the exsudative
enteropathy in only two of those previous cases [62,63].
Lymphoma may be related to PIL as a consequence of sev-
eral mechanisms: (1) long-standing protein-losing enter-
opathy may be resolved after treatment (chemotherapy
and/or radiotherapy) [62-64]; (2) lymphoma may cause
secondary intestinal lymphangiectasia, (3) lymphoma in
PIL could be associated with an immune deficiency.
Indeed, a primary deficiency of B cells and/or helper T
cells has been proposed in PIL, in combination with a sec-
ondary immune deficiency resulting from the loss of
immunoglobulins and lymphocytes [39,40]. But no clear
evidence of depressed intestinal immunity was found in
PIL patients compared to those with other primary immu-
nodeficiencies and having gut infections, like giardiasis.
B. Cutaneous warts
PIL patients were reported to have diffuse and multiple
cutaneous warts in association with lymphoma [65,66].
Widespread viral warts may be associated with a primary
immune deficiency in PIL or secondary to lymphoma.
C. Infections
Although PIL patients have moderate-to-severe hypogam-
maglobulinemia and lymphopenia, their risk of pyogenic
bacterial infection is not significantly elevated and oppor-
tunistic infections are uncommon. Only one case of a
severe infection with group G streptococcal empyema was
reported [67] and another had cryptococcal meningitis
[68].
D. Gelatinous transformation of the bone marrow
It is an uncommon disorder characterized by the replace-
ment of hematopoietic cells and adipocytes by amor-
phous extracellular material composed of acid
mucopolysaccharides. The only reported case of a gelati-
nous transformation of the bone marrow in a PIL patient
was attributed to the malnutrition resulting from malab-
sorption [69].
Management including treatment
A. Low-fat diet associated with medium-chain triglycerides
Low-fat diet associated with supplementary medium-
chain triglycerides (MCT) is the cornerstone of PIL medi-
cal management [70]. It is likely that the absence of fat in
the diet prevents engorgement of the intestinal lymphatics
with chyle, thereby preventing their rupture with its ensu-
ing protein and T-cell loss. MCT are directly absorbed into
the portal venous circulation and thus provide nutrient fat
but avoid lacteal engorgement. After a few weeks, this
treatment may lead to reversal of clinical and biochemical
signs (albuminemia, immunoglobulin levels and lym-
phocyte counts) [71]. In patients not responding to a low-
fat diet, enteral nutritional therapy (elemental, semi-ele-
mental and polymeric diets) may be required. In a few
very severe cases, total parenteral nutrition is warranted
[72]. The need for dietary control appears to be perma-
nent, because clinical and biochemical findings reappear
after low-fat diet withdrawal. Long-term PIL monitoring
essentially concerns its predominant clinical manifesta-
tion (edema). Laboratory analyses (albuminemia, lym-
phocyte counts, immunoglobulin levels) are required
when lower limb edema becomes more pronounced.
B. Other treatments
In the literature, other treatments have been proposed to
treat PIL. They can be used after or in combination with a
low-fat diet associated with MCT supplementation. Their
efficacy is variable and insufficiently evaluated.Orphanet Journal of Rare Diseases 2008, 3:5 http://www.ojrd.com/content/3/1/5
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1) Antiplasmin
A few authors reported that PIL patients responded to
tranexamic acid (1 g, 3 times a day) [73,74], but these
responses were heterogeneous with only partial disease
attenuation. It was hypothesized that increasing plasma
fibrinolysis might enhance lymphatic permeability to
plasma proteins. Under antiplasmin treatment, a lower
percentage of T lymphocytes became normalized together
with serum immunoglobulin values. In addition, the ther-
apy resulted in the disappearance endoscopically
observed duodenal lesions [73].
2) Octreotide
In 1998, Ballinger and Farthing reported the efficacy of
octreotide in one PIL patient [75]. To date, few publica-
tions have supported the contribution of octreotide in
PIL. Octreotide (150–200 µg, twice a day or the slow-
release formulation) might lead to clinical, biochemical
(albuminemia) and histological improvement [76,77].
The mechanism of action of the somatostatin analog on
the gastrointestinal tract remains unclear. It has been
shown that octreotide induces short-lasting splanchnic
vasoconstriction in healthy volunteers and cirrhotic
patients, and inhibits the absorption of triglycerides [78].
Furthermore, somatostatin inhibits thoracic lymph flow
in dogs [79]. Octreotide may be useful in PIL patients in
combination with a low-fat diet.
3) Surgery
Small bowel resection is useful in the rare cases in which
intestinal lymphangiectasia is segmental and localized
(duodenum) [80,81]. Recurrent and/or bulky pleural
effusions may lead to unilateral or bilateral surgical pleu-
rectomy or talc pleurodesis [5].
4) Corticosteroids
Steroids were prescribed to patients with intestinal lym-
phangiectasia secondary to inflammatory disease with
variable efficacy [82] and also to systemic lupus erythema-
tosus patients with protein-losing enteropathy [58]
5) Albumin infusion
Albumin infusion is a symptomatic treatment proposed
in patients with important serous effusion or uncomfort-
able lower limb edema. Repeated albumin intravenous
supplementation may be useful to reduce edema and
improve albuminemia but its efficacy is transient resulting
from persistent lymph leakage into the bowel lumen.
Prognosis and long-term outcome
PIL is a chronic debilitating disorder requiring constrain-
ing long-term dietary control based on a low-fat regimen
associated with supplementary MCT. Lower limb edema
is usually the main clinical manifestation but lymphe-
dema may be associated. Lower limb lymphedema had its
own particularities, including infectious complications
(e.g., cellulitis) and requires specific long-term manage-
ment (low-stretch bandage, manual lymph drainage, skin
care, elastic hosiery) [83]. These two conditions deterio-
rate the quality of life (difficulty to put on shoes, unattrac-
tive aspect of leg). PIL outcome may be severe even life-
threatening when malignant complications (lymphoma)
or serous effusion(s) (pleural, pericardic) occur.
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